Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COCP Cocrystal Pharma	$1.59 +2.3%	$1.61	$1.12 ▼ $3.26	$16.26M	2.07	41,950 shs	16,305 shs
CUE Cue Biopharma	$0.80 -2.9%	$0.79	$0.45 ▼ $1.99	$61.59M	1.53	254,719 shs	67,949 shs
GNTA Genenta Science	$3.83 +1.3%	$3.61	$2.74 ▼ $7.28	$70.07M	0.62	14,910 shs	6,564 shs
INMB INmune Bio	$2.09 +2.0%	$3.04	$1.89 ▼ $11.64	$55.55M	0.97	1.54 million shs	600,921 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COCP Cocrystal Pharma	+0.32%	+1.97%	-10.37%	-0.32%	-17.99%
CUE Cue Biopharma	-1.19%	+2.67%	+1.18%	+28.88%	+13.84%
GNTA Genenta Science	+7.39%	+11.21%	+0.77%	-11.50%	-7.80%
INMB INmune Bio	-5.09%	-13.14%	-29.55%	-72.15%	-70.96%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COCP Cocrystal Pharma	2.8597 of 5 stars	3.5	5.0	0.0	2.1	1.7	0.0
CUE Cue Biopharma	2.5983 of 5 stars	0.0	5.0	4.7	3.0	0.8	0.6
GNTA Genenta Science	2.3549 of 5 stars	3.5	3.0	0.0	2.5	1.7	0.0
INMB INmune Bio	2.0046 of 5 stars	3.3	2.0	0.0	1.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COCP Cocrystal Pharma	3.00	Buy	$6.00	278.55% Upside
CUE Cue Biopharma	0.00	N/A	N/A	N/A
GNTA Genenta Science	3.00	Buy	$25.00	552.57% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	780.38% Upside

Current Analyst Ratings Breakdown

Latest COCP, GNTA, INMB, and CUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/20/2025	COCP Cocrystal Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.52 per share	N/A
CUE Cue Biopharma	$8.29M	7.43	N/A	N/A	$0.24 per share	3.34
GNTA Genenta Science	N/A	N/A	N/A	N/A	$0.74 per share	N/A
INMB INmune Bio	$10K	5,555.22	N/A	N/A	$1.09 per share	1.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COCP Cocrystal Pharma	-$17.50M	-$1.24	N/A	N/A	N/A	N/A	-144.12%	-102.85%	11/12/2025 (Estimated)
CUE Cue Biopharma	-$40.67M	-$0.56	N/A	N/A	N/A	-469.35%	-230.13%	-111.16%	11/13/2025 (Estimated)
GNTA Genenta Science	-$9.64M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)

Latest COCP, GNTA, INMB, and CUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	COCP Cocrystal Pharma	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/12/2025	Q2 2025	CUE Cue Biopharma	-$0.13	-$0.09	+$0.04	-$0.09	$2.00 million	$2.95 million
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
GNTA Genenta Science	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COCP Cocrystal Pharma	N/A	3.69	3.69
CUE Cue Biopharma	0.01	1.60	1.60
GNTA Genenta Science	N/A	6.89	6.89
INMB INmune Bio	N/A	4.20	4.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COCP Cocrystal Pharma	6.72%
CUE Cue Biopharma	35.04%
GNTA Genenta Science	15.13%
INMB INmune Bio	12.72%

Insider Ownership

Company	Insider Ownership
COCP Cocrystal Pharma	28.14%
CUE Cue Biopharma	10.78%
GNTA Genenta Science	28.99%
INMB INmune Bio	35.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COCP Cocrystal Pharma	10	10.26 million	7.37 million	Not Optionable
CUE Cue Biopharma	60	76.85 million	68.56 million	Optionable
GNTA Genenta Science	7	18.29 million	12.99 million	Not Optionable
INMB INmune Bio	10	26.58 million	17.09 million	Optionable

COCP, GNTA, INMB, and CUE Headlines

Recent News About These Companies

INmune Bio, Inc. (NASDAQ:INMB) Receives $18.40 Consensus PT from Brokerages

August 23, 2025 | americanbankingnews.com

INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Recommendation of "Moderate Buy" by Brokerages

August 21, 2025 | marketbeat.com

INmune Bio Inc. Stock Grades | INMB | Barron's

August 16, 2025 | barrons.com

INmune Bio, Inc. (NASDAQ:INMB) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

BTIG Reaffirms Their Hold Rating on Inmune Bio (INMB)

August 10, 2025 | theglobeandmail.com

Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?

August 10, 2025 | finance.yahoo.com

Inmune Bio (INMB) was downgraded to a Sell Rating at Scotiabank

August 9, 2025 | theglobeandmail.com

Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s

August 9, 2025 | theglobeandmail.com

INmune Bio (INMB) Q2 Loss Widens 110%

August 8, 2025 | aol.comA

INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

INmune Bio stock soars after prostate cancer trial meets endpoints

August 4, 2025 | investing.com

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 4, 2025 | finance.yahoo.com

INmune Bio Shares Surge as Prostate Cancer Trial Achieves Key Goals

August 4, 2025 | msn.com

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 4, 2025 | globenewswire.com

INmune Bio (NASDAQ:INMB) Cut to Sell at Wall Street Zen

August 3, 2025 | marketbeat.com

INmune Bio options imply 14.9% move in share price post-earnings

August 1, 2025 | msn.com

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

July 31, 2025 | globenewswire.com

INmune Bio (INMB) to Release Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

July 29, 2025 | globenewswire.com

2BNS, INMB : INmune Bio Rebounds Sharply During After Hours Trading: What&...

July 28, 2025 | benzinga.com

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

July 25, 2025 | manilatimes.netM

New MarketBeat Followers Over Time

Media Sentiment Over Time

COCP, GNTA, INMB, and CUE Company Descriptions

Cocrystal Pharma NASDAQ:COCP

$1.58 +0.04 (+2.26%)

Closing price 03:51 PM Eastern

Extended Trading

$1.58 0.00 (0.00%)

As of 04:13 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Cue Biopharma NASDAQ:CUE

$0.80 -0.02 (-2.92%)

Closing price 04:00 PM Eastern

Extended Trading

$0.81 +0.00 (+0.56%)

As of 04:09 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Genenta Science NASDAQ:GNTA

$3.83 +0.05 (+1.32%)

As of 04:00 PM Eastern

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.

INmune Bio NASDAQ:INMB

$2.09 +0.04 (+1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 +0.02 (+0.72%)

As of 05:36 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time